Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Bullboard - Stock Discussion Forum ProMIS Neurosciences Inc PMN

ProMIS Neurosciences Inc. is a development stage biotechnology company. The Company is focused on generating and developing antibody therapeutics selectively targeting toxic misfolded proteins in neurodegenerative diseases such as Alzheimer’s disease (AD), amyotrophic lateral sclerosis (ALS) and multiple system atrophy (MSA), an alpha-synucleinopathy. Its proprietary target discovery engine... see more

NDAQ:PMN - Post Discussion

ProMIS Neurosciences Inc > PMN is top headline at alsnewstoday.com !
View:
Post by Gbathat on Sep 10, 2021 8:33am

PMN is top headline at alsnewstoday.com !

https://alsnewstoday.com/news-posts/2021/09/09/promis-neurosciences-validate-tdp-43-antibodies-als-treatment/
Comment by Speyeder999 on Sep 10, 2021 8:54am
Nice find Gbat, thanks for sharing
Comment by retiredcop on Sep 10, 2021 11:20am
A few of us have been waiting for a third party to bring this topic up... There could be a good reason why this info was published this week ( especially on a Friday???) ... I personally think it was a situation where PMN may have asked the writer a favour, we will let the ALS News group publish but if you could just wait for us to have something that could coincide with this news. We will give ...more  
Comment by Gbathat on Sep 10, 2021 8:48pm
This is impressive stuff.... "Because conventional antibodies have a hard time entering cells, ProMIS developed intrabodies targeting that same protein region. These antibodies are not delivered directly to cells, but their genetic sequence is, allowing cells to produce their own antibodies. Results so far have shown that exiting protein aggregates were cleared with these ...more  
The Market Update
{{currentVideo.title}} {{currentVideo.relativeTime}}
< Previous bulletin
Next bulletin >

At the Bell logo
A daily snapshot of everything
from market open to close.

{{currentVideo.companyName}}
{{currentVideo.intervieweeName}}{{currentVideo.intervieweeTitle}}
< Previous
Next >
Dealroom for high-potential pre-IPO opportunities